Search is Powered by Google
Breast Cancer News

New Breast Cancer Treatment Shows Promise In Early Application

Main Category: Breast Cancer
Also Included In: Radiology / Nuclear Medicine;  IT / Internet / E-mail;  Conferences
Article Date: 20 Nov 2007 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:5 stars

5 (3 votes)

Health Professional:5 stars

5 (2 votes)

Article Opinions: 0 posts

Physicians at the Rebecca and John Moores UCSD Cancer Center will present the initial outcomes of their use of a new device that delivers radiation therapy to a specific tumor site at the annual meeting of the Radiological Society of North America (RSNA), November 25-30, 2007, in Chicago, Illinois.

The Moores UCSD Cancer Center is one of the first medical facilities in the nation to offer patients this new form of breast conservation therapy, which combines surgery and radiation to treat breast cancer while preserving as much of the breast tissue as possible.

The UCSD team will report that a new technology called the SAVI™ applicator, which allows radiation to be delivered with precision to the cancerous site, avoiding healthy tissue, provides multiple benefits for patients, breast surgeons, and radiation oncologists.

The presentation, titled "Early Experience with the SAVI for Multi-Catheter Single Entry High-Dose Rate Breast Brachytherapy," will be given on Tuesday, Nov. 27h by Daniel Scanderbeg, Ph.D.

"This technology allows treatment of breast cancer with less radiation exposure to normal tissues and a significantly shorter treatment duration," said Catheryn Yashar, M.D., assistant professor and chief of breast and gynecological services in the UCSD Department of Radiation Oncology.

Breast conservation therapy includes lumpectomy the surgical removal of the cancerous tissue within the breast plus tissue immediately around the tumor followed by radiation. Traditionally, radiation therapy after a lumpectomy has involved treatment of the entire breast with external beam radiation. Known as whole breast irradiation, this approach exposes more healthy tissue and requires a much longer treatment course, with radiation delivered five times a week over a six-to-seven week period.

Partial breast radiation is an advancement in breast conservation therapy (lumpectomy plus radiation) as it treats a smaller amount of normal breast tissue and takes significantly less time to administer. Partial breast radiation is usually completed in approximately one week allowing women to more quickly resume their normal activities. Although early reports on partial breast irradiation are promising, the definitive study comparing it to whole breast radiation is currently underway by the National Surgical Breast and Bowel Project (NSABP).

The SAVI applicator is a single-entry, multi-catheter device that delivers partial breast irradiation. It was developed to expand the benefits of breast conservation therapy to a larger group of women, owing to its multi-catheter design which allows the precise delivery of radiation to avoid critical structures such as the skin, chest wall, and lungs, thus targeting more high risk areas and sparing more normal tissue.

"Our early experience with SAVI has been excellent," said Yashar. "We were able to reproducibly treat the lumpectomy site and avoid healthy tissue such as the skin, chest wall and lungs because the radiation dose is precisely targeted. The device is also well tolerated by the patient and relatively easy for the physician to place."

Yashar and her colleagues report that treatment with the applicator is effective in multiple ways. SAVI can be inserted using local anesthesia, is nearly painless to remove, and has produced outstanding early cosmetic results. Additionally, treatment planning is not significantly more difficult than other techniques and daily monitoring can be done with X-rays rather than full CT scans. This approach is more convenient and substantially reduces the patient's exposure to radiation.

The SAVI (Strut-Adjusted Volume Implant) applicator is made by Cianna Medical, Inc., a women's health company dedicated to the innovative treatment of early-stage breast cancer.

About the Moores UCSD Cancer Center

The Rebecca and John Moores UCSD Cancer Center is located at the University of California, San Diego. Founded in 1979, the Moores UCSD Cancer Center is one of just 39 centers in the United States to hold a National Cancer Institute (NCI) designation as a Comprehensive Cancer Center. As such, it ranks among the top centers in the nation conducting basic and clinical cancer research, providing advanced patient care and serving the community through outreach and education programs. Moores Cancer Center membership includes one Nobel Laureate, fourteen members of the National Academy of Sciences (UCSD is ranked 7th in the total number of NAS members), one member of the Advisory Council of the NCI, and a past president of the American Association for Cancer Research. For more information, access http://cancer.ucsd.edu.

University of California, San Diego
200 West Arbor Dr.
San Diego, CA 92103
United States
http://www.ucsd.edu


Personalized Homepage Weekly Newsletters Daily News Alerts
Opioid Induced Constipation ADHD Anxiety Asthma Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles All 'How To...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
Understanding And Treating Triple-Negative Breast Cancer
07 Jan 2009
Triple-negative breast cancer is a subtype of breast cancer that is clinically negative for expression of estrogen and progesterone receptors (ER/PR) and HER2 protein. It is characterized by its unique molecular profile...


Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

Breast Cancer Treatment: Get Involved image Breast Cancer Treatment: Get Involved

Today, breast cancer patients may be treated by a multidisciplinary team of specialists, consisting of nurses, oncologists, surgeons, social workers, nutritionists and genetic counselors. However, patients, too, have a critical role in their treatment...

View more videos...